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Exacerbations of chronic obstructive pulmonary disease (COPD) are important events that carry significant
consequences for patients. Some patients experience frequent exacerbations, and are now recognized as a distinct
clinical subgroup, the ‘frequent exacerbator’ phenotype. This is relatively stable over time, occurs across disease
severity, and is associated with poorer health outcomes. These patients are therefore a priority for research and
treatment. The pathophysiology underlying the frequent exacerbator phenotype is complex, with increased airway
and systemic inflammation, dynamic lung hyperinflation, changes in lower airway bacterial colonization and a
possible increased susceptibility to viral infection. Frequent exacerbators are also at increased risk from comorbid
extrapulmonary diseases including cardiovascular disease, gastroesophageal reflux, depression, osteoporosis and
cognitive impairment. Overall these patients have poorer health status, accelerated forced expiratory volume over 1
s (FEV1) decline, worsened quality of life, and increased hospital admissions and mortality, contributing to increased
exacerbation susceptibility and perpetuation of the frequent exacerbator phenotype. This review article sets out the
definition and importance of the frequent exacerbator phenotype, with a detailed examination of its
pathophysiology, impact and interaction with other comorbidities.
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ComorbiditiesIntroduction
Exacerbations of chronic obstructive pulmonary disease
(COPD) are episodes of symptom worsening in COPD
that have both short-term and longer-term conse-
quences [1]. They are associated with increased airway
and systemic inflammation and also increases in dy-
namic hyperinflation leading to classical exacerbation
symptoms [2]. COPD exacerbations are major drivers of
health status in COPD, and are important causes of hos-
pital admission and death. Exacerbations are also key
outcomes for therapies in COPD and thus there has
been much progress in their understanding in recent
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reproduction in any medium, provided the orIt has also been recognized that some patients with
COPD are particularly susceptible to exacerbations and
these patients have been termed ‘frequent exacerbators’,
in contrast to patients with infrequent exacerbations who
experience few exacerbations over time. The frequent
exacerbator phenotype has now been recognized as a
major phenotype in patients with COPD and occurs across
disease severities. The Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints (ECLIPSE) ex-
acerbation study showed that even in patients defined as
grade 2 according to the Global Initiative for Chronic
Obstructive Pulmonary Disease (GOLD) (forced expira-
tory volume over 1 s (FEV1) 50% to 80% predicted), 22%
of the COPD population were frequent exacerbators [3]
(Figure 1). Therefore, this review will describe the patho-
physiology and impact of the frequent exacerbator pheno-
type and will also address the interaction with
comorbidity, as illustrated in Figure 2.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Association of disease severity with the frequency and
severity of exacerbations. Reproduced from Hurst et al. [3] with
permission.
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frequent exacerbator phenotype
COPD exacerbations have been defined in two ways.
Exacerbations are episodes of worsening of symptoms,
and can be defined in terms of a persisting deterioration
in respiratory symptoms outside normal day-to-day vari-
ation, In the London COPD cohort work [4], an exacer-
bation is defined as an increase of two major symptoms
(either dyspnea, increased sputum purulence or in-
creased sputum volume), or one major and one minor
symptom (cough, wheezing, cold, nasal discharge, sore
throat), sustained for 2 days or longer. Use of such aFigure 2 Schematic illustration of the frequent exacerbator phenotyp
(COPD) experience exacerbations, there is a subgroup of patients who ente
outcome. This phenotype appears to be maintained over time.definition requires some form of daily monitoring with
either a diary or an electronic device, but allows a
complete count of all exacerbation events. It has been
shown that exacerbations are often unreported and un-
treated and that these untreated exacerbations also affect
health status [4-6]. Symptom measures for COPD exac-
erbations are therefore likely to be optimal for exacerba-
tion detection in clinical trials [7].
Recently the EXACT-PRO (‘EXAcerbations of Chronic
Pulmonary Disease Tool - Patient-Reported Outcome’)
device has been developed as a validated outcome tool
for COPD exacerbations and this is based on detecting
changes in symptoms and thus registering events
whether treated or untreated [8]. Epidemiological studies
and clinical trials have both used healthcare utilization
(HCU) as a measure of COPD exacerbations, though as
explained above, these definitions are inaccurate, will
vary with different healthcare systems, and will miss un-
treated events. Furthermore, many patients with COPD
are slow to perceive exacerbation symptoms and thus
will tend not to report exacerbations for therapy. It
should also be noted that COPD exacerbations may
mimic or coexist with other conditions, such as pneu-
monia, congestive cardiac failure, pneumothorax or pul-
monary embolism, and thus it is important in clinical
practice to accurately confirm the diagnosis and exclude
other conditions.
Thus, the precise definition of the frequent exacerbator
phenotype is problematic and will represent the number
of exacerbations where a stable phenotype is present over
time. The ECLIPSE exacerbation analysis showed thate. While many patients with chronic obstructive pulmonary disease
r a destructive cycle of frequent exacerbations with associated poorer
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year in 1 year, they have around a 68% chance of having
two or more in the third year [3]. However, if both treated
and untreated events are counted, as in the London co-
hort of patients with COPD, then the exacerbation rate
for a stable phenotype will be larger. Further studies are
required to address this issue.Pathophysiology of frequent COPD exacerbations
The heterogeneity of COPD exacerbations reflects their
dependence on a complex spectrum of interacting fac-
tors. Susceptibility to exacerbations and the basis of the
frequent exacerbator is therefore probably multifactorial.
Identifying contributory factors, such as background air-
way inflammation, airway microbial patterns and host
immunological responses, may provide potential targets
in the effort to alter a patient’s exacerbation frequency
phenotype.Airway and systemic inflammation at exacerbation and in
the frequent exacerbator
During exacerbations of COPD the existing airway and
systemic inflammation associated with this inflammatory
disease increases further [9-14]. An inflammatory cascade
releases inflammatory mediators, such as interleukins and
chemokines, which recruit and activate immune cells.
This cascade is thought to contribute to the local struc-
tural damage responsible for COPD progression, but also
causes systemic inflammation with increases in acute
phase proteins such as fibrinogen [11] and C reactive pro-
tein (CRP) [15]. Although the exacerbation inflammatory
process is predominantly neutrophilic [16,17], the num-
bers of all inflammatory cell types within bronchial mu-
cosa increase and the inflammatory character is also
influenced by the type of insult triggering an exacerba-
tion. For example, compared to bacterially driven exac-
erbations viruses appear to stimulate more eosinophil
activity [17,18].
The airways of frequent exacerbators, however, appear
to be more inflamed with higher levels of sputum inter-
leukin (IL)-6 and IL-8 even in the stable state [9]. In
addition, their trajectory of inflammation is also worse
with sputum IL-6 and plasma fibrinogen [19] continuing
to increase more rapidly over time.
Frequent exacerbators have higher sputum IL-6 and
serum CRP during their exacerbation recovery periods
[20], making persistent post-exacerbation inflammation
a possible explanation for their higher baseline inflam-
mation. A higher CRP during the recovery period is also
associated with a shorter time until the next exacerba-
tion [20] perhaps suggesting an inflammatory basis to
the temporal clustering of exacerbations reported by
Hurst et al., who identified the 8-week post-exacerbationperiod as particularly high risk for exacerbation recur-
rence [21].
Persisting and increased propensity to inflammation
therefore is a feature of the frequent exacerbator pheno-
type, although whether these features are causative or
are downstream of susceptibility to the triggers of exac-
erbations remains to be established.
Mechanical factors
Small airway obstruction in COPD is accompanied by
dynamic lung hyperinflation and this is a major driver of
respiratory symptoms, particularly dyspnea [22]. At ex-
acerbation, airway inflammation and worsened expira-
tory flow limitation worsen this, leading to further
dynamic hyperinflation with increased respiratory effort,
cardiovascular strain, inspiratory muscle overload and
potential respiratory failure [2]. In those patients with
severe airflow obstruction and a lower FEV1% predicted,
hyperinflation is more likely to be present even in stable
disease and there may be reduced capacity to deal with
any further insult. Exacerbations would potentially be
more easily triggered in these patients and this may ex-
plain why a higher exacerbation frequency is seen with
more severe airflow restriction.
Bronchodilator therapy, by improving small airway ob-
struction, has been shown to reduce lung hyperinflation
in stable disease and therefore may partially ‘reset’ the
threshold at which exacerbation occurs [23]. This pro-
vides a mechanism by which bronchodilator therapy
may reduce exacerbation frequency even in the absence
of any anti-inflammatory effects.
Triggers of COPD exacerbations
Most exacerbations appear to be associated with infect-
ive triggers, either bacterial or viral, although ‘non-
infective’ triggers such as air pollution may also be
important. Most of the 40% of acute exacerbations
linked to viral infections involve rhinovirus (58%)
although other respiratory viruses implicated include
human respiratory syncytial virus, coronavirus, influenza
virus, parainfluenza virus and adenoviruses [24,25].
These viral associated exacerbations exhibit greater sys-
temic or airway inflammation, greater symptom burden
and longer recovery times [9,11,24].
Susceptibility to viral infection, COPD and the frequent
exacerbator phenotype
An increased viral susceptibility has been proposed as a
cause of more frequent exacerbations in COPD [25].
Cigarette smoking does appear to increase viral suscepti-
bility [26,27] but whether or not the overall COPD popu-
lation itself is more susceptible is disputed. Data from an
analysis in the London COPD cohort showed that upper
airway colds are more likely to occur in patients with a
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patients have enhanced susceptibility to viral infection
[28]. There is also evidence that patients in whom a re-
spiratory virus is detected have a higher exacerbation fre-
quency [24]. Monto et al., in an early study, demonstrated
that patients with chronic bronchitis had a greater inci-
dence of serologically proven rhinovirus infection [29] al-
though this work involved small study groups, lacked
spirometric measurements and preceded molecular viral
detection techniques. Further support for the viral suscep-
tibility theory came from Wald et al., who studied a rhino-
virus outbreak within a care facility and found that
patients with COPD were over-represented in the infected
group [30]. However, contradicting these findings is the
work by Greenberg et al. who, again using small groups,
found no excess incidence of viral respiratory infections in
patients with COPD versus controls, though frequent
exacerbators were not specifically studied in this paper
[31]. Well-powered studies are required to firmly establish
whether the frequent exacerbator phenotype in particular
experiences a greater proportion of viral exacerbations
than infrequent exacerbators.
There are a number of proposed mechanisms of in-
creased viral susceptibility including modulation of intra-
cellular adhesion molecule 1 (ICAM-1). Most rhinovirus
serotypes (major group) attach to respiratory epithelial
cells by binding to ICAM-1 [32] and through this trans-
membrane protein modulate the recruitment and activa-
tion of inflammatory cells. Increased ICAM-1 increases
susceptibility to infection and ICAM-1 appears to be
upregulated in the bronchial mucosa of patients with
chronic bronchitis [33].
While viruses are separately thought to be a major
cause of COPD exacerbations, 25% of exacerbations in-
volve coinfection with viruses and bacteria. These exac-
erbations exhibit greater functional impairment, with
longer hospitalization [17,24], and are associated with
higher airway bacterial load and greater airway inflam-
mation [34]. Recent work using rhinovirus inoculation
as an experimental model of COPD exacerbation shows
a consistent increase in bacterial numbers following the
initial viral infection [35] and this supports the hypoth-
esis that bacterial exacerbation may be precipitated by
viruses.
Bacterial infection and COPD exacerbations
Common bacteria associated with many COPD exacer-
bations include Streptococcus pneumoniae, Haemophilus
influenzae, and Moraxella catarrhalis [36] and their
presence at exacerbation is accompanied by greater
levels of systemic inflammation [37]. Besides the intro-
duction of these bacterial species or an increase in their
bacterial load, it has also become clear that even a
change in bacterial strain can trigger exacerbations [38].In the absence of active infection, the identification, by
traditional culture methods, of bacteria in the lower air-
way has been termed ‘colonization’. This term gives the
illusion that such bacterial presence is benign, yet it is
actually associated with greater inflammation, poorer
lung function [37], chronic bronchitis [39-41], and more
frequent exacerbations [42].
With the development of new molecular techniques it
is clear that even the healthy lower airway is not sterile
[43] and so we must re-evaluate the meaning of previ-
ously identified colonization and the mechanism by which
it influences exacerbation frequency. Colonization may ac-
tually represent a disturbance of the normal microbiome,
with subsequent overgrowth of a particular species, which
drives the inflammatory process in COPD. Alternatively, it
may be the inflammatory process that impairs normal regu-
lation of bacterial presence making colonization a marker
and potential amplifier of underlying inflammatory damage
rather than its primary driver. Longitudinal studies are re-
quired to establish how the airway microbiome changes at
exacerbation and how this relates to colonization and the
frequent exacerbator phenotype.
Genetic predisposition of exacerbation susceptibility
The existence of a seemingly distinct exacerbator pheno-
type raises the question of whether there is a genetic
predisposition towards frequent exacerbations in COPD.
This question has not yet been clearly answered, although
some distinct gene polymorphisms appear to be linked to
exacerbation frequency. Takabatake and colleagues [44]
reported that a single nucleotide polymorphism in the
CCL-1 gene, encoding a leucocyte chemotactic factor, was
predictive of the frequency and severity of exacerbations,
while polymorphic variation in surfactant protein B has
also been linked with exacerbation frequency [45].
Mannose-binding lectin (MBL) deficiency is associated
with susceptibility to respiratory infections; a higher fre-
quency of MBL gene polymorphisms was noted in pa-
tients with COPD who experience frequent exacerbations
[46] and may also predict hospital admission for COPD
[47]. In addition to these, an increased exacerbation fre-
quency was found in patients whose sputum contained
markers suggestive of increased microsatellite DNA in-
stability, suggesting that those patients with a higher DNA
mutation rate experience more frequent exacerbations
[48]. Further research is needed to explore this further.
Adherence to medications
It has been suggested that half of all patients do not take
their medications adequately [49], and these patients
may be missing the benefit of therapies that would
otherwise reduce exacerbation frequency. Treatments
for COPD are varied, including rehabilitation, smoking
cessation, oxygen therapy as well as medications
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ence is therefore complex and difficult to measure; it
may differ between therapies and even in individual pa-
tients [50]. However, patients who are non-adherent to
COPD therapy experience more frequent hospitaliza-
tions [51] and have greater healthcare utilization than
those who adhere [52], and therefore non-adherence
may be another etiological factor in the development of
the frequent exacerbator phenotype. Factors linked to
non-adherence include age, complexity of treatment
regimen, nature of inhaled delivery device, patient edu-
cation, and importantly depression [53], which is itself
common in COPD and linked to exacerbation frequency
as described below.
Impact of frequent exacerbations in patients with
COPD
Lung function decline
Over the last 15 years, the importance of frequent exac-
erbations on disease progression and patient reported
outcomes has become increasingly apparent. Exacerba-
tions were once considered to be of little or no import-
ance. This was based on the pivotal 10-year study by
Fletcher and colleagues, which found no relationship be-
tween lung function decline and chest infections [54].
However, their patient cohort had only limited airflow
obstruction. In patients with moderate to severe COPD,
two studies initially showed that frequent exacerbations
accelerate lung function decline. Donaldson and col-
leagues [55] reported a 25% faster decline in FEV1
(−32.1 mL/year vs −40.1 mL/year; P <0.05) in patients
with frequent exacerbations. Kanner and colleagues [56]
reported on patients with mild COPD who continued to
smoke; in this group, experiencing 1.5 lower respiratory
tract illnesses per year was associated with a decline in
FEV1 of −69.4 ml/year, compared to a decline of −55.9
ml/year. Larger interventional or observational studies
have subsequently confirmed these findings and the ef-
fect of exacerbations on disease progression [57-61].
Quality of life
It has been known for some time that frequent exacerba-
tions have a profound impact on the health status of pa-
tients with COPD. Seemungal and colleagues reported
that patients with three or more exacerbations per year
(both treated and untreated) had a poorer health-related
quality of life compared patients with zero to two exac-
erbations per year, as measured with the disease specific
St. Georges Respiratory Questionnaire (SGRQ) [4]. Re-
cently, other measures of health status, such as the
COPD assessment test (CAT), have shown a worse score
in frequent exacerbators with >2 exacerbations per year
of 19.5 compared to 16.8 in patients with <2 exacerba-
tions per year [62].The impact of exacerbations as assessed by the SGRQ
in a study also persists for some time after the event, as
patients only approached baseline within the next 6
months [63]. Other assessment measures show faster
rates of improvement, and in patients who did not re-
lapse with another exacerbation, significant improve-
ments were seen in the four domains of the Chronic
Respiratory Questionnaire (CRQ) between presentation
and 10 days later [64].
Feelings of fatigue are also impacted with the Func-
tional Assessment of Chronic Illness Therapy-fatigue
(FACIT-fatigue) scale, showing worsening of fatigue at
exacerbation and worsening of scores with increasing
exacerbation frequency [65].
Activity
Peripheral muscle weakness is associated with COPD ex-
acerbations, and muscle force (quadriceps peak torque)
was found to be lower at 3 days after admission for an
exacerbation than 90 days later [66]. An acute fall in
outdoor activity is also seen at exacerbation [67] and a
number of factors may contribute: physical inactivity,
bed rest, metabolic, nutritional and inflammatory status
and steroid treatment [68]. Exacerbations also appear to
have a permanent effect on physical activity; patients
with frequent exacerbations (>2.47 per year) have a
faster decline in time outdoors each day of −0.17 h/year
(P <0.011) in addition to the decline of −0.10 h/year that
occurs in infrequent exacerbators [67].
Hospital admissions
Patients with a history of frequent exacerbations are
those also most likely to be admitted to hospital. In the
ECLIPSE exacerbation study, patients with GOLD stage
2 COPD (FEV1 50% to 80% predicted) already had a 7%
admission rate to hospital for COPD exacerbation-
related causes over the first year of follow-up, and this
increased to 33% of patients admitted over a year with
stage 4 disease (FEV1 less than 30% predicted) [3]. There
is evidence that delayed therapy for an exacerbation
leads to longer exacerbations and a higher chance of
hospital admission. Thus, patients must be instructed
about symptom recognition and the importance of early
intervention [5].
Mortality
There is a wide range reported of inpatient mortality
from COPD exacerbations, which reflects comorbidity
and admission practices. Risk factors for inpatient mor-
tality include cor pulmonale, congestive heart failure, a
low arterial pH, leg edema, age, oxygen saturations <86%,
assisted ventilation and low body mass index [69,70]. A
UK audit showed that larger general hospitals and
Figure 3 Annual rate of myocardial infarction against the
annual rate of exacerbation (defined as prescription of steroids
and antibiotics together). Reproduced from Donaldson et al. [86]
with permission.
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small district general hospitals [71].
Frequent acute exacerbations are also an independent
risk factor for all-cause mortality in COPD [72], and
every hospitalized exacerbation worsens disease progres-
sion. The risk of death is increased by up to five times
following the tenth admission compared to the first [73].
Exacerbation frequency and comorbidities
Cardiovascular comorbidity
Cardiovascular diseases form the largest group of
comorbidities seen in patients with COPD, with ische-
mic heart disease (IHD) the most important condition.
Prevalence estimates vary; a pooled analysis of 2 large
epidemiological studies involving 20,296 patients in the
USA [74] reported a prevalence of 20% to 22% in pa-
tients with COPD compared to 9% in controls, with
even symptomatic patients with early COPD with nor-
mal spirometry at increased risk. Patients with comorbid
IHD in the London COPD cohort had longer exacerba-
tions, worse health status, more dyspnea and a lower ex-
ercise capacity than those without [75].
Systemic inflammation, a predominant feature of
COPD, is strongly associated with cardiovascular risk.
Chronic inflammation is associated with the develop-
ment and rupture of atherosclerotic plaques [76], and C
reactive protein, elevated in patients with COPD,
predicts cardiovascular events [77]. Levels of the inflam-
matory marker IL-6 are also higher in patients with
COPD with cardiovascular disease [78] and frequent
exacerbators have higher levels of IL-6 and fibrinogen
than infrequent exacerbators [19]. Systemic inflamma-
tion contributes to a prothrombotic state, increasing the
likelihood of cardiovascular and thromboembolic events
[79]. Cardiovascular risk is also linked to vascular dys-
function. Large vessel arterial stiffness strongly predicts
cardiovascular events and mortality [80] and is raised in
patients with COPD [81], while small vessel dysfunction
is suggested by higher levels of microalbuminuria [82]
and cerebral small vessel disease [83]. Hypertension, a
key risk factor for further cardiovascular events, is prob-
ably also linked to vascular dysfunction and is described
in 40% to 60% of patients with COPD compared to 34%
of controls [74].
Exacerbations have a profound and direct impact on
patients’ cardiovascular status. Of 242 patients hospital-
ized for COPD exacerbation in Scotland, 12% were
found to meet universally agreed criteria for the diagno-
sis of myocardial infarction with raised troponin and
either chest pain or serial electrocardiogram (ECG)
changes [84]. The period following an exacerbation ap-
pears to be particularly high risk. In the 4-year UPLIFT
trial, the relative risks of cardiac failure, myocardial
infarction and stroke were 10.71, 3.20 and 2.31respectively, in 2,289 patients, for the 180 days after
their first exacerbation compared to the 180 days
preceding it [85]. In addition, evidence from a large ob-
servational database in the UK showed a 2.27-fold in-
creased risk of clinical myocardial infarction in the first
5 days after an exacerbation and a 1.26-fold increased
risk of stroke in the first 49 days afterwards [86]; pa-
tients who experienced myocardial infarction or stroke
had a higher yearly exacerbation frequency than those
who did not (Figure 3). Pulmonary embolism may be
also associated with COPD exacerbations, though the
reported prevalence of pulmonary embolism is variable
[87]. However, patients with exacerbations complicated
by pulmonary embolism have a poorer outcome [79].
Treatment of cardiovascular disease and hypertension
is therefore a priority for patients with COPD, especially
frequent exacerbators. Secondary prevention for cardio-
vascular events usually involves antiplatelet agents,
statins, β-blockers and angiotensin-converting enzyme
inhibitors, and there is evidence that these reduce mor-
tality in COPD [88-90]. Cardioselective β-blockers ap-
pear safe and beneficial in COPD [91,92] and may also
reduce admissions due to exacerbations [93]. Low-
molecular-weight heparin is effective at reducing the risk
of venous thromboembolism in patients hospitalized
with respiratory illness [94] and should be considered in
all inpatients with COPD exacerbation.
Gastroesophageal reflux disease (GORD)
GORD is present in up to 30% to 60% of patients with
COPD [95] and there is growing evidence to suggest that
it plays an important role in exacerbations. Two studies
have reported a higher exacerbation frequency in pa-
tients with GORD symptoms [96,97], and the large
Wedzicha et al. BMC Medicine 2013, 11:181 Page 7 of 10
http://www.biomedcentral.com/1741-7015/11/181ECLIPSE study showed an association between self-
reported GORD and having ≥2 treated exacerbations per
year [3]. Although the etiology remains unclear, there is a
plausible causative mechanism by way of microaspiration
of stomach contents causing increased airway inflamma-
tion and potentiated by the effect of hyperinflation com-
mon in COPD. The reflux is complex, with non-acid and
gaseous reflux likely to be prominent in COPD. This po-
tentially represents a novel therapeutic target, and a
single-blind trial of 100 patients with COPD showed a sig-
nificant reduction in exacerbations from 1.18 to 0.32 over
1 year of treatment with lansoprazole 15 mg daily [98]
despite excluding patients with clinically overt GORD.
Further research is needed into the causes and mecha-
nisms of GORD in COPD and whether other agents
modifying gastric motility may be more appropriate
interventions.
Neuropsychiatric complications
Depression is common in patients with COPD; the
ECLIPSE study found a prevalence of symptom-defined
depression in 26% of patients compared to 12% of con-
trols, increasing with disease severity [99]. There is a
clear relationship to exacerbation frequency, and fre-
quent exacerbators have higher depression scores even
at baseline; patients who are depressed have worse
breathlessness and quality of life, are more socially iso-
lated and spend less time outdoors [100]. Depression in
COPD is also linked to poorer outcomes including hos-
pital readmission and all-cause mortality [101,102].
Given that depression is a risk factor for poor engage-
ment with many aspects of healthcare, including medi-
cation adherence [103] and completion of pulmonary
rehabilitation programs [104], these patients may receive
inadequate treatment for their COPD and this may fur-
ther contribute to the poor outcomes above. Depressive
symptoms should be recognized and treated alongside
the underlying COPD.
Impaired cognitive function is increasingly recognized
in COPD, at exacerbation in particular. A recent pro-
spective study showed that patients with COPD had sig-
nificantly worse cognitive function than controls, with
those who had just recovered from an exacerbation sig-
nificantly worse than those at stable state [105]. Cru-
cially, there was no recovery at 3 months. This suggests
that exacerbations are associated with sustained cogni-
tive dysfunction, and frequent exacerbators may there-
fore be subject to more rapid cognitive decline.
Osteoporosis
Osteoporosis is common, with a reported prevalence of
35% in patients with COPD [106], and is related to the
degree of emphysema seen on computerized tomog-
raphy (CT) scan [107]. These patients are often alreadyat increased risk due to comorbidities and relative in-
activity, and this prevalence is not fully explained by
corticosteroid use alone [106]. Thoracic vertebral com-
pression fractures due to osteoporosis cause back pain
and worsening kyphosis and are associated with a de-
crease in vital capacity (previously quantified as 9% per
fracture [108]). Frequent exacerbators have a much lar-
ger annual decrease in bone mineral density compared
to infrequent exacerbators (5.41% vs 0.60%) [109], and
are therefore more likely to be susceptible to fractures.
Therefore, these patients should be carefully investigated
for osteoporosis and treated as appropriate.
Conclusions
This review has described the impact of the frequent
exacerbator phenotype on patients with COPD and their
considerable morbidity. Frequent exacerbators can be
identified across the COPD disease spectrum and must
be targeted for effective exacerbation prevention, both
with pharmacological and non-pharmacological agents.
Susceptibility to respiratory viral infection is likely to be
an important mechanism in frequent exacerbators and
novel interventions need to be developed to reduce viral
infection at exacerbation. There is now some evidence
that interventional therapy with an anti-inflammatory
agent can modify the frequent exacerbator phenotype
such that patients become infrequent exacerbators [110].
By understanding the mechanisms of development of
frequent exacerbations, and applying appropriate inter-
ventions, we will be at last able to impact on the health
status of this high-risk patient group.
Abbreviations
CAT: COPD assessment test; COPD: Chronic obstructive pulmonary disease;
CRP: C reactive protein; CRQ: Chronic respiratory questionnaire;
CT: Computerized tomography; ECLIPSE: Evaluation of COPD longitudinally
to identify predictive surrogate endpoints; FACIT-Fatigue: Functional
assessment of chronic illness therapy-fatigue scale; FEV1: Forced expiratory
volume over 1 s; GOLD: Global initiative for chronic obstructive pulmonary
disease; GORD: Gastroesophageal reflux disease; ICAM: Intracellular adhesion
molecule; IHD: Ischemic heart disease; IL: Interleukin; MBL: Mannose-binding
lectin; SGRQ: St George’s respiratory questionnaire.
Competing interests
JAW has received honoraria for lectures and/or advisory boards from GSK,
Boehringer, Bayer, Novartis, Vifor Pharma, Chiesi, Pfizer, Takeda and Almirall.
JAW has also received research grant funding from Takeda, GSK, Novartis
and Chiesi. SEB, JPA and GCD have no competing interests to declare.
Authors’ contributions
All the authors contributed to the writing of the review and performed the
literature searches. All authors were involved at all stages of the editing
process and have seen and approved the final manuscript.
Received: 17 May 2013 Accepted: 9 July 2013
Published: 14 August 2013
References
1. Wedzicha JA, Seemungal TAR: COPD exacerbations: defining their cause
and prevention. Lancet 2007, 370:786–796.
Wedzicha et al. BMC Medicine 2013, 11:181 Page 8 of 10
http://www.biomedcentral.com/1741-7015/11/1812. O’Donnell DE, Parker CM: COPD exacerbations. 3: Pathophysiology. Thorax
2006, 61:354–361.
3. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B,
Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha
JA, Evaluation of COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic
obstructive pulmonary disease. N Eng J Med 2010, 363:1128–1138.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA:
Effect of exacerbation on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418–1422.
5. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA: Early
therapy improves outcomes of exacerbations of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2004, 169:1298–1303.
6. Langsetmo L, Platt RW, Ernst P, Bourbeau J: Underreporting exacerbation
of chronic obstructive pulmonary disease in a longitudinal cohort. Am J
Respir Crit Care Med 2008, 177:396–401.
7. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF,
D’Andrea P, Arrasate C, Chen H, Banerji D: Analysis of chronic obstructive
pulmonary disease exacerbations with the dual bronchodilator QVA149
compared with glycopyrronium and tiotropium (SPARK): a randomised,
double-blind, parallel-group study. Lancet Respir Med 2013, 1:199–209.
8. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S: Standardizing
measurement of chronic obstructive pulmonary disease exacerbations,
reliability and validity of a patient-reported diary. Am J Respir Crit Care
Med 2011, 183:323–329.
9. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum
inflammatory markers to symptoms and lung function changes in COPD
exacerbations. Thorax 2000, 55:114–120.
10. Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute
bacterial exacerbations of chronic bronchitis: the role of leukotriene B4.
Eur Respir J 2000, 15:274–280.
11. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC,
Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of chronic
obstructive pulmonary disease are accompanied by elevations of plasma
fibrinogen and serum IL-6 levels. Thromb Haemost 2000, 84:210–215.
12. Gompertz S, O’Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial
inflammation during acute exacerbations of chronic bronchitis. Eur Respir
J 2001, 17:1112–1119.
13. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W:
Oxidative stress and airway inflammation in severe exacerbations of
COPD. Thorax 2005, 60:293–300.
14. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA: Systemic
and upper and lower airway inflammation at exacerbation of chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:71–78.
15. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel
FX: Value of C-reactive protein measurements in exacerbations of
chronic obstructive pulmonary disease. Respir Med 1998, 92:664–667.
16. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK:
Biopsy neutrophilia, neutrophil chemokine and receptor gene
expression in severe exacerbations of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2003, 168:968–975.
17. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G,
Fabbri LM, Johnston SL: Infections and airway inflammation in chronic
obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care
Med 2006, 173:1114–1121.
18. Saha S, Brightling CE: Eosinophilic airway inflammation in COPD. Int J
Chron Obstruct Pulmon Dis 2006, 1:39–47.
19. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR,
Maccallum PK, Wedzicha JA: Airway and systemic inflammation and decline
in lung function in patients with COPD. Chest 2005, 128:1995–2004.
20. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC,
Wedzicha JA: Inflammatory changes, recovery and recurrence at COPD
exacerbation. Eur Respir J 2007, 29:527–534.
21. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha
JA: Temporal clustering of exacerbations in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2009, 179:369–374.
22. O’Donnell DE, Laveneziana P: The clinical importance of dynamic lung
hyperinflation in COPD. COPD 2006, 3:219–232.
23. Wedzicha JA, Decramer M, Seemungal TA: The role of bronchodilator
treatment in the prevention of exacerbations of COPD. Eur Respir J 2012,
40:1545–1554.24. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S,
Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA: Respiratory
viruses, symptoms, and inflammatory markers in acute exacerbations
and stable chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2001, 164:1618–1623.
25. Wedzicha JA: Role of viruses in exacerbations of chronic obstructive
pulmonary disease. Proc Am Thorac Soc 2004, 1:115–120.
26. Cohen S, Tyrrell DA, Russell MA, Jarvis MJ, Smith AP: Smoking, alcohol
consumption, and susceptibility to the common cold. Am J Public Health
1993, 83:1277–1283.
27. Harris JM 2nd, Gwaltney JM Jr: Incubation periods of experimental
rhinovirus infection and illness. Clin Infect Dis 1996, 23:1287–1290.
28. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA:
Epidemiological relationships between the common cold and
exacerbation frequency in COPD. Eur Respir J 2005, 26:846–852.
29. Monto AS, Bryan ER: Susceptibility to rhinovirus infection in chronic
bronchitis. Am Rev Respir Dis 1978, 118:1101–1103.
30. Wald TG, Shult P, Krause P, Miller BA, Drinka P, Gravenstein S: A rhinovirus
outbreak among residents of a long-term care facility. Ann Intern Med
1995, 123:588–593.
31. Greenberg SB, Allen M, Wilson J, Atmar RL: Respiratory viral infections in
adults with and without chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000, 162:167–173.
32. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA: A cell
adhesion molecule, ICAM-1, is the major surface receptor for
rhinoviruses. Cell 1989, 56:849–853.
33. Di Stefano A, Maestrelli P, Roggeri A, Turato G, Calabro S, Potena A, Mapp
CE, Ciaccia A, Covacev L, Fabbri LM, Saetta M: Upregulation of adhesion
molecules in the bronchial mucosa of subjects with chronic obstructive
bronchitis. Am J Respir Crit Care Med 1994, 149:803–810.
34. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA:
Effect of interactions between lower airway bacterial and rhinoviral
infection in exacerbations of COPD. Chest 2006, 129:317–324.
35. Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB,
Kebadze T, Aniscenko J, Oleszkiewicz G, Gray K, Message SD, Ito K, Barnes
PJ, Adcock IM, Papi A, Stanciu LA, Elkin SL, Kon OM, Johnson M, Johnston
SL: Rhinovirus infection induces degradation of antimicrobial peptides
and secondary bacterial infection in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2012, 186:1117–1124.
36. Stockley RA: Lung infections. 1. Role of bacteria in the pathogenesis and
progression of acute and chronic lung infection. Thorax 1998, 53:58–62.
37. Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC,
McHugh TD, Wedzicha JA: Changes in prevalence and load of airway
bacteria using quantitative PCR in stable and exacerbated COPD.
Thorax 2012, 67:1075–1080.
38. Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and
exacerbations of chronic obstructive pulmonary disease. N Eng J Med
2002, 347:465–471.
39. Monso E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, Morera J: Risk
factors for lower airway bacterial colonization in chronic bronchitis. Eur
Respir J 1999, 13:338–342.
40. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway
inflammation and bronchial microbial patterns in patients with stable
chronic obstructive pulmonary disease. Eur Respir J 1999, 14:1015–1022.
41. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between
airway bacterial load and markers of airway inflammation in patients
with stable chronic bronchitis. Am J Med 2000, 109:288–295.
42. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha
JA: Relationship between bacterial colonisation and the frequency,
character, and severity of COPD exacerbations. Thorax 2002, 57:759–764.
43. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P:
Lung microbiology and exacerbations in COPD. Int J Chron Obstruct
Pulmon Dis 2012, 7:555–569.
44. Takabatake N, Shibata Y, Abe S, Wada T, Machiya J, Igarashi A, Tokairin Y, Ji
G, Sato H, Sata M, Takeishi Y, Emi M, Muramatsu M, Kubota I: A single
nucleotide polymorphism in the CCL1 gene predicts acute exacerbations
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006,
174:875–885.
45. Foreman MG, DeMeo DL, Hersh CP, Carey VJ, Fan VS, Reilly JJ, Shapiro SD,
Silverman EK: Polymorphic variation in surfactant protein B is associated
with COPD exacerbations. Eur Respir J 2008, 32:938–944.
Wedzicha et al. BMC Medicine 2013, 11:181 Page 9 of 10
http://www.biomedcentral.com/1741-7015/11/18146. Lin CL, Siu LK, Lin JC, Liu CY, Chian CF, Lee CN, Chang FY: Mannose-
binding lectin gene polymorphism contributes to recurrence of infective
exacerbation in patients with COPD. Chest 2011, 139:43–51.
47. Yang IA, Seeney SL, Wolter JM, Anders EM, McCormack JG, Tunnicliffe AM,
Rabnott GC, Shaw JG, Dent AG, Kim ST, Zimmerman PV, Fong KM:
Mannose-binding lectin gene polymorphism predicts hospital
admissions for COPD infections. Genes Immun 2003, 4:269–274.
48. Makris D, Tzanakis N, Damianaki A, Ntaoukakis E, Neofytou E, Zervou M,
Siafakas NM, Tzortzaki EG: Microsatellite DNA instability and COPD
exacerbations. Eur Respir J 2008, 32:612–618.
49. Bender BG: Nonadherence to COPD treatment: what have we learned
and what do we do next? COPD 2012, 9:209–210.
50. Bourbeau J: Patient adherence in COPD. Thorax 2008, 63:7.
51. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh
MS: Treatment of COPD: relationships between daily dosing frequency,
adherence, resource use, and costs. Respir Med 2011, 105:435–441.
52. Simoni-Wastila L, Wei YJ, Qian J, Zuckerman IH, Stuart B, Shaffer T, Dalal AA,
Bryant-Comstock L: Association of chronic obstructive pulmonary disease
maintenance medication adherence with all-cause hospitalization and
spending in a Medicare population. Am J Geriatr Pharmacother 2012,
10:201–210.
53. Makela MJ, Backer V, Hedegaard M, Larsson K: Adherence to inhaled
therapies, health outcomes and costs in patients with asthma and
COPD. Respir Med 2013.
54. Fletcher C, Peto R, Tinker CM, Speizer FE: The Natural History of Chronic
Bronchitis and Emphysema. Oxford, UK: Oxford University Press; 1976.
55. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship
between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax 2002, 57:847–852.
56. Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses
promote FEV(1) decline in current smokers but not ex-smokers with
mild chronic obstructive pulmonary disease: results from the lung health
study. Am J Respir Crit Care Med 2001, 164:358–364.
57. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW,
Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on
rate of decline of lung function in chronic obstructive pulmonary
disease: results from the TORCH study. Am J Respir Crit Care Med 2008,
178:332–338.
58. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C:
Correlating changes in lung function with patient outcomes in chronic
obstructive pulmonary disease: a pooled analysis. Respir Res 2011, 12:161.
59. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM,
Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK,
Tal-Singer R, Wouters E, Rennard SI, ECLIPSE Investigators: Changes in
forced expiratory volume in 1 second over time in COPD. N Eng J Med
2011, 365:1184–1192.
60. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP: Exacerbation
frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012,
7:653–661.
61. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic
Emili J, Tzanakis N: Exacerbations and lung function decline in COPD:
new insights in current and ex-smokers. Respir Med 2007, 101:1305–1312.
62. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA:
Usefulness of the chronic obstructive pulmonary disease assessment test
to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med
2012, 185:1218–1224.
63. Spencer S, Jones PW: Time course of recovery of health status following
an infective exacerbation of chronic bronchitis. Thorax 2003, 58:589–593.
64. Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hebert PC:
Measurement of short-term changes in dyspnea and disease-specific quality
of life following an acute COPD exacerbation. Chest 2002, 121:688–696.
65. Baghai-Ravary R, Quint JK, Goldring JJ, Hurst JR, Donaldson GC, Wedzicha
JA: Determinants and impact of fatigue in patients with chronic
obstructive pulmonary disease. Respir Med 2009, 103:216–223.
66. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P,
Bouillon R, Decramer M: Muscle force during an acute exacerbation in
hospitalised patients with COPD and its relationship with CXCL8 and
IGF-I. Thorax 2003, 58:752–756.
67. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA:
Exacerbations and time spent outdoors in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2005, 171:446–452.68. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Physical
activity and hospitalization for exacerbation of COPD. Chest 2006,
129:536–544.
69. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson
WJ, Kussin P, Bellamy P, Goldman L, Knaus WA: Outcomes following acute
exacerbation of severe chronic obstructive lung disease. The SUPPORT
investigators (Study to Understand Prognoses and Preferences for
Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996,
154:959–967.
70. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG: Clinical
audit indicators of outcome following admission to hospital with acute
exacerbation of chronic obstructive pulmonary disease. Thorax 2002,
57:137–141.
71. Roberts CM, Barnes S, Lowe D, Pearson MG: Evidence for a link between
mortality in acute COPD and hospital type and resources. Thorax 2003,
58:947–949.
72. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro
M, Ochando R: Severe acute exacerbations and mortality in patients with
chronic obstructive pulmonary disease. Thorax 2005, 60:925–931.
73. Suissa S, Dell’Aniello S, Ernst P: Long-term natural history of chronic
obstructive pulmonary disease: severe exacerbations and mortality.
Thorax 2012, 67:957–963.
74. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes
of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir
J 2008, 32:962–969.
75. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR: The impact of
ischemic heart disease on symptoms, health status, and exacerbations in
patients with COPD. Chest 2012, 141:851–857.
76. Libby P, Okamoto Y, Rocha VZ, Folco E: Inflammation in atherosclerosis:
transition from theory to practice. Circ J 2010, 74:213–220.
77. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells
L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M,
Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E,
Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA,
Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-
Smith G, Deeg D, et al: C-reactive protein, fibrinogen, and cardiovascular
disease prediction. N Eng J Med 2012, 367:1310–1320.
78. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, Van Empel VP, Bruijnzeel
PL, Rutten EP, Op TRoodt J, Wouters EF, Franssen FM: Clusters of
comorbidities based on validated objective measurements and systemic
inflammation in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2013, 18:728–735.
79. Bertoletti L, Quenet S, Mismetti P, Hernandez L, Martin-Villasclaras JJ, Tolosa
C, Valdes M, Barron M, Todoli JA, Monreal M: Clinical presentation and
outcome of venous thromboembolism in COPD. Eur Respir J 2012,
39:862–868.
80. Vlachopoulos C, Aznaouridis K, Stefanadis C: Prediction of cardiovascular
events and all-cause mortality with arterial stiffness: a systematic review
and meta-analysis. J Am Coll Cardiol 2010, 55:1318–1327.
81. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE,
Murchison JT, Macnee W: Arterial stiffness is independently associated
with emphysema severity in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2007, 176:1208–1214.
82. Casanova C, de Torres JP, Navarro J, Aguirre-Jaime A, Toledo P, Cordoba E,
Baz R, Celli BR: Microalbuminuria and hypoxemia in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2010,
182:1004–1010.
83. van Dijk EJ, Vermeer SE, de Groot JC, van de Minkelis J, Prins ND, Oudkerk
M, Hofman A, Koudstaal PJ, Breteler MM: Arterial oxygen saturation, COPD,
and cerebral small vessel disease. J Neurol Neurosurg Psychiatry 2004,
75:733–736.
84. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O’Connor J,
McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W:
Diagnosis of myocardial infarction following hospitalisation for
exacerbation of COPD. Eur Respir J 2012, 39:1097–1103.
85. Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP: Risk of
nonlower respiratory serious adverse events following COPD
exacerbations in the 4-year UPLIFT(R) trial. Lung 2011, 189:261–268.
86. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA: Increased risk
of myocardial infarction and stroke following exacerbation of COPD.
Chest 2010, 137:1091–1097.
Wedzicha et al. BMC Medicine 2013, 11:181 Page 10 of 10
http://www.biomedcentral.com/1741-7015/11/18187. Rizkallah J, Man SF, Sin DD: Prevalence of pulmonary embolism in acute
exacerbations of COPD: a systematic review and metaanalysis.
Chest 2009, 135:786–793.
88. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM:
Reduction of morbidity and mortality by statins, angiotensin-converting
enzyme inhibitors, and angiotensin receptor blockers in patients with
chronic obstructive pulmonary disease. J Am Coll Cardiol 2006,
47:2554–2560.
89. Ekstrom MP, Hermansson AB, Strom KE: Effects of cardiovascular drugs on
mortality in severe chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2013, 187:715–720.
90. Dobler CC, Wong KK, Marks GB: Associations between statins and COPD: a
systematic review. BMC Pulm Med 2009, 9:32.
91. Salpeter S, Ormiston T, Salpeter E: Cardioselective beta-blockers for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005,
4, CD003566.
92. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW: Beta-blockers may
reduce mortality and risk of exacerbations in patients with chronic
obstructive pulmonary disease. Arch Intern Med 2010, 170:880–887.
93. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ: Effect of beta
blockers in treatment of chronic obstructive pulmonary disease: a
retrospective cohort study. BMJ 2011, 342:d2549.
94. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon
C, Leizorovicz A, Olsson CG, Turpie AG: Prevention of venous
thromboembolism in medical patients with enoxaparin: a subgroup
analysis of the MEDENOX study. Blood Coagul Fibrinol 2003, 14:341–346.
95. Patel AR, Hurst JR: Extrapulmonary comorbidities in chronic obstructive
pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5:647–662.
96. Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR,
Nahman NS, Vega KJ: Role of gastroesophageal reflux symptoms in
exacerbations of COPD. Chest 2006, 130:1096–1101.
97. Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, Kinose D, Ogawa E,
Hoshino Y, Niimi A, Terada T, Mishima M: Impact of gastro-oesophageal
reflux disease symptoms on COPD exacerbation. Thorax 2008,
63:951–955.
98. Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, Arai H,
Araya J, Kuwano K, Yamaya M: A randomized, single-blind study of
lansoprazole for the prevention of exacerbations of chronic obstructive
pulmonary disease in older patients. J Am Geriatr Soc 2009, 57:1453–1457.
99. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF,
Rennard SI, Sharafkhaneh A: Determinants of depression in the ECLIPSE
chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med
2011, 183:604–611.
100. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA: Relationship
between depression and exacerbations in COPD. Eur Respir J 2008,
32:53–60.
101. de Voogd JN, Wempe JB, Koeter GH, Postema K, van Sonderen E, Ranchor
AV, Coyne JC, Sanderman R: Depressive symptoms as predictors of
mortality in patients with COPD. Chest 2009, 135:619–625.
102. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW: Acute exacerbations of
chronic obstructive pulmonary disease and the effect of existing
psychiatric comorbidity on subsequent mortality. Psychosomatics 2011,
52:441–449.
103. Khdour MR, Hawwa AF, Kidney JC, Smyth BM, McElnay JC: Potential risk
factors for medication non-adherence in patients with chronic
obstructive pulmonary disease (COPD). Eur J Clin Pharmacol 2012,
68:1365–1373.
104. Keating A, Lee A, Holland AE: What prevents people with chronic
obstructive pulmonary disease from attending pulmonary rehabilitation?
A systematic review. Chron Respir Dis 2011, 8:89–99.
105. Dodd JW, Charlton RA, van den Broek MD, Jones PW: Cognitive
dysfunction in patients hospitalized with acute exacerbation of chronic
obstructive pulmonary disease (COPD). Chest. in press.
106. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V: The
prevalence of osteoporosis in patients with chronic obstructive
pulmonary disease: a cross sectional study. Respir Med 2007, 101:177–185.
107. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E,
Hoshino Y, Niimi A, Chin K, Mishima M: Relationship between pulmonary
emphysema and osteoporosis assessed by CT in patients with COPD.
Chest 2008, 134:1244–1249.doi:10.1186/1741-7015-11-181
108. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR: Osteoporosis-
related kyphosis and impairments in pulmonary function: a systematic
review. J Bone Miner Res 2007, 22:447–457.
109. Kiyokawa H, Muro S, Oguma T, Sato S, Tanabe N, Takahashi T, Kudo M,
Kinose D, Kondoh H, Kubo T, Hoshino Y, Ogawa E, Hirai T, Mishima M:
Impact of COPD exacerbations on osteoporosis assessed by chest CT
scan. COPD 2012, 9:235–242.
110. Wedzicha JA, Rabe KF, Martinez FJ, Bredenbroker D, Brose M, Goehring UM,
Calverley PM: Efficacy of roflumilast in the chronic obstructive pulmonary
disease frequent exacerbator phenotype. Chest 2013, 143:1302–1311.
Cite this article as: Wedzicha et al.: Mechanisms and impact of the
frequent exacerbator phenotype in chronic obstructive pulmonary
disease. BMC Medicine 2013 11:181.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
